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During the first trimester of pregnancy, spiral arteries (SA) within the maternal uterus (decidua and myometrium) 
are remodeled from small diameter vessels with a low flow at 
high resistance, to those with a large diameter and high flow at 
low resistance. This transformation results in vessels that are 
not responsive to vasoconstrictors and provide increased blood 
flow to the fetus at a reduced pressure. Complete physiological 
remodeling of the SA is achieved only in the presence of fetal 
extravillous trophoblast (EVT).1 EVT are specialized cells that 
migrate both into the decidual stroma and retrograde to flow 
in the lumen of SA, where they are termed endovascular tro-
phoblast.2 Endovascular trophoblast disrupt the interactions of 
the endothelial cells (EC) and vascular smooth muscle cells 
(VSMC) making up the SA, and eventually mediate the loss of 
these cells through mechanisms thought to involve apoptosis 
and dedifferentiation.3 Endovascular trophoblast then replace 
the cells they have displaced, and adopt a more endothelial-
like phenotype,4 before reendothelialization occurs.
Defects in this unique remodeling process have been 
associated with the onset of pregnancy disorders, including 
preeclampsia, intrauterine growth restriction, and preterm 
labor. Although the symptoms of these disorders commonly 
present later in pregnancy, inadequate SA remodeling is 
proposed to occur during the first trimester.5 Relatively 
little is known regarding the mechanisms of normal SA 
remodeling because of the difficulties of studying early 
human pregnancy. Animal models are limited because of 
the lack of deep trophoblast invasion and SA transformation 
in other species.6 Therefore, there is a need to model these 
multicellular interactions in vitro. Previous models include 
the use of monolayer cocultures,7 explant cultures,8 and 
endothelial capillary tubes on Matrigel.9 These have revealed 
the secretion of a number of factors by endovascular 
trophoblast which impact on the physiological changes that 
occur in SA remodeling, including the secretion of proteases 
to degrade the extracellular matrix and disrupt cellular 
interactions,10 and chemokines including interleukin (IL)-
8, MCP-1,11 and IL-6.12 Trophoblast also induce reduced 
expression and disruption of EC adhesion molecules, 
such as E-cadherin,13 and apoptosis of vascular cells.14,15 
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Objective—During pregnancy, fetal trophoblast disrupt endothelial cell and vascular smooth muscle cell (VSMC) interactions 
in spiral arteries of the maternal decidua to enable increased nutritional and oxygen delivery to the fetus. Little is known 
regarding this transformation because of difficulties of studying human pregnancy in vivo. This study investigated how 
trophoblast-secreted factors affect the interactions of vascular cells and the differentiation status of VSMC during spiral 
arteries remodeling using 3-dimensional vascular spheroid coculture.
Methods and Results—Endothelial cell and VSMC were cocultured in hanging droplets to form spheroids representing 
an inverted vessel lumen. Control or conditioned media from an extravillous trophoblast (EVT) cell line was incubated 
with vascular spheroids for 24 hours. Spheroid RNA was then analyzed by Illumina Sentrix BeadChip array. Spheroids 
incubated with EVT conditioned medium showed significant up/downregulation of 101 genes (>1.5-fold; P<0.05), 
including an upregulation of C-X-C motif chemokine 10 (IP-10). C-X-C motif chemokine 10 expression was confirmed 
by qualitative real-time PCR and Western blot analysis of spheroids, and immunohistochemistry of first trimester 
decidua and ex vivo dissected nonplacental bed spiral arteries. EVT conditioned medium reduced VSMC expression of 
differentiation markers, and both EVT conditioned medium and C-X-C motif chemokine 10 increased motility of VSMC 
indicating dedifferentiation of VSMC.
Conclusion—EVT-induced C-X-C motif chemokine 10 expression may contribute to spiral arteries remodeling during pregnancy 
by altering the motility and differentiation status of the VSMC in the vessel. (Arterioscler Thromb Vasc Biol. 2013;33:e93-e101)
Key Words: CXCL10/IP-10 ◼ spiral artery remodeling ◼ 3D culture ◼ trophoblast ◼ vascular smooth muscle cell
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Furthermore, EC and VSMC are not passive observers of 
the remodeling process and respond to trophoblast with 
alterations in protease production,16 cell motility,17 adhesion 
properties,12 and cytokine production.11
The use of 3-dimensional (3D) spheroid cell culture mod-
els may overcome some limitations of both monolayer cells 
and ex vivo explants in studying the initial stages of human 
placentation, as cells grown in 3D cultures retain a phenotype 
more similar to in vivo than in monolayer.18 Vascular spher-
oids show some of the phenotypic properties of vessels, such 
as differentiation of EC as demonstrated by a downregulation 
of platelet-derived growth factor expression, CD34 expres-
sion, and a reduction in apoptosis.19 A similarity to the struc-
ture of the vessel wall is also retained, with a monolayer of 
EC over a core of VSMC, however limitations are presented 
by the lack of connective tissue and shear stress present in a 
vessel. In this study, we used this 3D multicellular model to 
investigate changes in gene expression within the vasculature 
in response to trophoblast secreted factors using a genome-
wide microarray. Expression of C-X-C motif chemokine 10 
(CXCL10; previously known as IP-10), a protein found to be 
upregulated in the array, has been reported in both EC and 
VSMC in response to proinflammatory stimuli,20,21 as well 
as some uterine EC in vivo.22 CXCL10 has also previously 
been implicated in vessel destabilization, and therefore we 
investigated its role in SA remodeling and found that IFN-
γ may be involved in the induction of CXCL10 in SA, and 
that EVT conditioned medium (CM) and CXCL10 contribute 
toward VSMC dedifferentiation and motility, key steps in the 
remodeling process.
Materials and Methods
Expanded methods are available in the online-only Data Supplement.
Cell Culture
The human vascular smooth muscle cell line SGHVSMC-9 (VSMC), 
human endothelial cell line SGHEC-7 (EC), and human EVT cell line 
SGHPL-4 were maintained, as previously described.15,23,24
Generation of EVT CM
SGHPL-4 cells were grown in 3D culture, as previously described,24 
and CM collected after 24 hours, as described in the Methods in the 
online-only Data Supplement.
Spheroid Generation
To generate spheroids, a hanging drop VSMC/EC coculture (750 
cells each) method was used.25,26
Microarray Analysis
RNA isolation, microarray analysis, and SYBR green quantitative 
real-time PCR was carried out, as described in the Methods in the 
online-only Data Supplement.
Western Blot Analysis
Spheroids (n=64) and monolayer VSMC were lysed in 50 µL RIPA 
buffer and Western blot analysis was carried out by standard proce-
dure using rabbit anti-CXCL10, mouse antiα-smooth muscle actin, 
or rabbit anticalponin.
Ex Vivo Vessel Explant Model
Informed consent was obtained and ethical committee approval was 
in place for all studies. Decidual/myometrial biopsies (n=3) were 
obtained from nonplacental bed areas from pregnant women under-
going elective Caesarean section at term for reasons such as breech 
presentation. SA were dissected, as previously described.8 Vessels 
were incubated with EVT CM for 24 hours, when arteries were cryo-
sectioned for immunohistochemical staining.
Immunohistochemistry
All immunohistochemistry was carried out by standard procedures 
described in the online-only Data Supplement.
Microscopy
Confocal and time-lapse microscopy was carried out, as described in 
the online-only Data Supplement.
Statistical Analysis
Nonparametric statistical analysis was applied where appropriate. 
Mann–Whitney tests were used to analyze quantitative PCR data, 
and the Friedman test with Dunns post hoc test was used to analyze 
experiments with multiple variables. Analysis was carried out using 
GraphPad Prism (GraphPad Software, San Diego, CA). Data are pre-
sented as mean±SEM.
Results
Vascular Spheroids Form a Monolayer 
of EC Surrounding a Core of VSMC
To investigate the effect of trophoblast on the interaction of 
EC and VSMC in the remodeling SA, we used coculture vas-
cular spheroids. To confirm that the orientation of EC and 
VSMC modeled a vessel, EC and VSMC were fluorescently 
labeled for confocal imaging. After 24 hours, the EC orien-
tated to the exterior of the spheroid in a monolayer, as previ-
ously described (Figure 1A),19 whereas the VSMC formed an 
internal core (Figure 1B). This culture system reestablished 
the orientation and cellular interactions between the EC 
monolayer and the underlying VSMC seen in the intact ves-
sel in vivo (Figure 1C), and therefore was used to model the 
effects of endovascular trophoblast within the lumen of SA.
101 Genes Were Significantly Altered by  
Trophoblast CM
To analyze changes in gene expression in the vasculature 
induced by trophoblast-secreted factors, trophoblast CM gen-
erated from the EVT cell line SGHPL-4 grown in 3D was 
added to vascular spheroids and incubated for 24 hours. The 
resulting cRNA was hybridized to Illumina Sentrix BeadChip 
Array and data analyzed, as described in the Methods in the 
online-only Data Supplement. The comparison revealed 101 
genes that were significantly altered >1.5-fold in CM-treated 
vascular spheroids as compared with control (C)-treated 
vascular spheroids (P<0.05; Table I in the online-only Data 
Supplement). Of these, 9 were downregulated and 92 were 
upregulated. A total of 10 genes showed a significant upregu-
lation of over >2-fold (P<0.05; Table). These genes were 
members of diverse families, which included cytokines, che-
mokines, and growth factors and included of particular interest 
chemokine (C-X-C motif) ligand 10 (CXCL10), chemokine 
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(C-C motif) ligand 20, stanniocalcin-1, IL-6, CD93, IL-11, 
platelet-derived growth factor, and placental growth factor. The 
full list was further analyzed by gene ontology analysis, and 
this revealed 36 significant biological processes (P<0.05) each 
containing between 2 and 54 genes (listed in full in Table II in 
the online-only Data Supplement). Of interest were ontologies 
relating to both cell proliferation and negative proliferation, 
response to wounding, various ontologies relating to signaling 
(including signal transduction, cell communication, cell–cell 
signaling), inflammatory response, and cell migration as well 
as some vascular processes (including angiogenesis, blood 
vessel development, and vascular development).
Microarray Verification
To verify the results of the array, quantitative real-time PCR 
was performed for the transcripts of CXCL10 (Figure 2A), 
stanniocalcin-1 (Figure 2B), and placental growth factor 
(Figure 2C) using independently isolated RNA samples to 
those used for array analysis. This analysis confirmed a statis-
tically significant increase in mRNA expression in CM-treated 
vascular spheroids of CXCL10 (7.9-fold, P<0.05; Figure 2A), 
stanniocalcin-1 (2.3-fold, P<0.05; Figure 2B), and placental 
growth factor (3.4-fold, P<0.05; Figure 2C), as compared with 
control-treated spheroids. A time course over 48 hours was 
carried out to examine CXCL10 mRNA expression, which 
was found to peak at 24 hours (Figure I in the online-only 
Data Supplement).
CXCL10 Protein Is Expressed by Vascular 
Spheroids in Response to Trophoblast CM
The expression of CXCL10 was chosen for further inves-
tigation, as it has previously been implicated in vessel 
destabilization in other vascular beds, however, mostly relat-
ing to its effects on EC.27,28 To further confirm the upregula-
tion of CXCL10 by EVT CM in vascular spheroids, Western 
blot analysis was performed. Spheroids were formed of EC 
alone, VSMC alone, and in coculture. After 24 hours treat-
ment, there was a small increase in CXCL10 protein expres-
sion when EC or VSMC were cultured alone, although this 
did not reach statistical significance. When EC and VSMC 
were cocultured in spheroids, there was a significant increase 
in CXCL10 expression of 3.7-fold in EC/VSMC spheroids 
treated with CM as compared with control (P<0.05; Figure 
3A). The fold increase in CXCL10 protein expression in EC/
VSMC spheroids was greater than the additive effect of the 
cell types cultured separately.
CXCL10 protein expression was also investigated by 
immunocytochemistry in vascular spheroids treated with con-
trol media or EVT CM. Cells positive for CXCL10 expression 
could be identified in sections of spheroids treated with control 
media (Figure 3B), however increased CXCL10 immunore-
activity was observed in vascular spheroids treated with EVT 
CM (Figure 3C). This appeared primarily to be present in the 
VSMC core; however, it could also be identified in the EC.
CXCL10 Expression in Ex Vivo SA 
and First Trimester Decidua
To confirm the expression of CXCL10 in a physiological set-
ting, CXCL10 protein was examined by immunohistochem-
istry of serial sections of first trimester decidua. CXCL10 
immunoreactivity was found widely throughout the stroma in 
all decidual sections examined (n=5; Figure 4A, and magni-
fication Figure 4C). We could colocalize CXCL10 expression 
with α-smooth muscle actin expression, indicating CXCL10 
Figure 1. Endothelial cell (EC) and vas-
cular smooth muscle cell (VSMC) spon-
taneously orientate to mimic features of a 
vessel lumen. (A) EC (green channel) and 
(B) VSMC (red channel) were cocultured 
in equal numbers in hanging droplets to 
form 3-dimensional (3D) vascular spher-
oid cocultures (C, merge) and examined 
by confocal microscopy.
Table.  Vascular Spheroid Gene Expression Altered >2-Fold by Trophoblast Conditioned Media
Gene Name/Symbol Fold Change (Absolute) Up/Down Corrected P Value
Homo sapiens CD93 molecule (CD93) 2.59 up 0.00625
Homo sapiens stanniocalcin 1 (STC1) 2.34 up 0.00188
Homo sapiens chemokine (C-C motif) ligand 20 (CCL20) 2.27 up 0.03741
Homo sapiens podocalyxin-like (PODXL), transcript variant 1 2.27 up 0.01122
Homo sapiens chemokine (C-X-C motif) ligand 10 (CXCL10) 2.24 up 0.02034
Homo sapiens interleukin 6 (interferon, beta 2) (IL6) 2.202 up 0.0266
Homo sapiens tissue factor pathway inhibitor 2 (TFPI2) 2.20 up 0.01540
Homo sapiens transmembrane protein 158 (TMEM158) 2.15 up 0.00625
Homo sapiens interleukin 11 (IL11) 2.14 up 0.00866
Homo sapiens placental growth factor (PGF) 2.01 up 0.01540
 at St George's, University of London on February 28, 2013http://atvb.ahajournals.org/Downloaded from 
e96  Arterioscler Thromb Vasc Biol  March 2013
expression by VSMC (Figure 4C and 4D, marked by arrow-
heads). Interestingly, cells expressing both smooth muscle 
actin and CXCL10 were also found a small distance away 
from the lumen of the artery. This was at a time when tropho-
blasts were present in the decidua (CK7 immunohistochemis-
try, B). CXCR3 expression was also examined in the decidua, 
and was also found to be localized to α-smooth muscle actin 
expression at a time when trophoblasts were present in the 
decidua (Figure II in the online-only Data Supplement).
The role of EVT CM in inducing expression of CXCL10 
was then examined in SA isolated from biopsies of nonplacen-
tal bed decidua/myometrium. SA were dissected and incubated 
with EVT CM for 24 hours. CXCL10 protein expression was 
examined by immunohistochemistry (Figure 4). Expression of 
CXCL10 (green channel) in the EC (red channel, identified by 
VWF immunostaining) and VSMC component (merge) was 
identified in arteries treated with EVT CM (Figure 4E–4G).
CXCL10 Expression Is Partly Induced by IFN-γ
IFN-γ is a well-known stimulant of CXCL10, and recombinant 
IFN-γ can induce CXCL10 expression in vascular spheroids 
(Figure 5A). Previous studies have shown that EVT secrete 
IFN-γ.29 We next examined whether IFN-γ in EVT CM was 
responsible for the induction of CXCL10 expression in the 
vascular spheroids. When IFN-γ was removed from EVT CM 
(using an IFN-γ–blocking antibody), before incubation with 
EC/VSMC spheroids for 24 hours, CXCL10 expression was 
reduced by an average of 4.5-fold as compared with CM incu-
bated with control mouse IgG (P<0.05; Figure 5B).
Effect of CXCL10 and EVT CM on VSMC
CXCL10 has been previously shown to alter functional dedif-
ferentiation markers of VSMC, including motility.30 During 
SA remodeling, this process may play a key role. Therefore, 
to determine a potential effect on SA of CXCL10 production, 
recombinant CXCL10 or EVT CM was added to cultures 
of VSMC for a period of 24 or 72 hours. The differentia-
tion markers α-smooth muscle actin and calponin, motility 
and proliferation of VSMC were assessed after 72 hours. 
EVT CM significantly decreased the expression of α-smooth 
muscle actin (Figure 6A) and calponin (Figure 6B), indicat-
ing a switch to a noncontractile, dedifferentiated phenotype. 
Recombinant CXCL10 induced a small decrease in expres-
sion of these markers that did not reach statistical significance. 
Motility of VSMC was significantly and dose-dependently 
increased over 24 hours in response to CXCL10 (Figure 6C; 
10 ng: 1.4-fold; 100 ng: 1.57-fold, P<0.05; 200 ng: 1.61-fold). 
Treatment of VSMC with EVT CM for 24 hours also signifi-
cantly increased cell motility (Figure 6D; 71 ng protein/µL: 
1.67-fold; 141 ng protein/µL: 1.9-fold, P<0.05).
Figure 2. C-X-C motif chemokine 10 (CXCL10), stanniocalcin-1, and placental growth factor mRNA expression is significantly increased 
by trophoblast conditioned media (CM). Messenger RNA expression in vascular spheroids was measured by quantitative real-time PCR 
after stimulation with trophoblast CM for 24 hours (n=4). Data are expressed as mRNA expression relative to an external calibrator. A, 
CXCL10. B, Stanniocalcin-1. C, Placental growth factor. All data are presented as mean±SEM. *P<0.05.
Figure 3. C-X-C motif chemokine 10 (CXCL10) protein is 
expressed by vascular spheroids stimulated with trophoblast con-
ditioned media. A, Vascular spheroid lysates were examined by 
Western blot analysis for the presence of CXCL10. Tubulin was 
used as an internal loading control. The image shown is represen-
tative of 3 independent experiments. Densitometric analysis of 
Western blots (n=3) with mean±SEM CXCL10/tubulin presented 
as a fold-change over control-treated spheroids. *P<0.05. Vascu-
lar spheroids treated with control media (B) or trophoblast condi-
tioned media (C) were cryosectioned and sections were examined 
by immunostaining for the presence of CXCL10. Sections were 
taken through approximately the center of the spheroid. Negative 
control incubated with rabbit IgG in place of primary antibody is 
inset. Scale bar,100 µm.
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Discussion
Interactions between EC and VSMC are crucial to the sta-
bility of a vessel, and physical contact between these cells 
contributes to the phenotype and differentiation status of 
both cell types.19 During decidual SA remodeling in the first 
trimester of pregnancy, this communication is disrupted and 
the structural integrity of the vessel is altered. This process 
is poorly understood because of the difficulties of accessing 
human implantation sites at this time and the lack of appro-
priate animal models.6 However, understanding the role of 
fetal trophoblast in the disruption of the stable interactions 
between cells in the vessel wall of SA is crucial to our under-
standing of pathologies associated with inadequate vascu-
lar remodeling. This study aimed to examine the effect of 
trophoblast on EC and VSMC interactions using a vascular 
spheroid 3D coculture model. We determined that tropho-
blast induce a number of gene expression changes in the 
vasculature, including an upregulation of CXCL10, a protein 
not previously associated with SA remodeling. We examined 
the expression of CXCL10 in an ex vivo SA model and in 
first trimester decidual tissue, where it could be localized 
to α-smooth muscle actin positive cells. Finally, we dem-
onstrated that trophoblast-secreted factors induced dedif-
ferentiation and increased cellular motility of VSMC, a key 
process in decidual SA remodeling, and that this was, in part, 
because of CXCL10.
Gene profiling established 101 differentially expressed 
genes between vascular spheroids cultured with trophoblast 
CM and control medium. Gene ontology analysis identified 
that the genes most significantly altered were associated with 
vascular development. These included the cytokine chemo-
kine (C-C motif) ligand 20 and the protease MMP-10, both of 
which have been associated with pathological vascular remod-
eling.27,28 MMP-10 degrades collagen type IV and laminin 
Figure 4.  C-X-C motif chemokine 10 (CXCL10) protein is expressed by first trimester decidua and dissected spiral arteries stimulated 
with trophoblast conditioned media. CXCL10 (A and C) and α-smooth muscle actin protein (D) expression was examined by immunohis-
tochemistry in serially sectioned first trimester decidua (n=5; representative image shown). CXCL10 and α-smooth muscle actin protein 
colocalized to the same cells (indicated by arrowheads). Trophoblasts (labeled with CK7, B) were present at this stage of remodeling. 
Negative control (inset) was incubated with nonimmune IgG in place of primary antibody. Scale bar represents 100 µm or 50 µm in zoom. 
(E) Expression of CXCL10 (green) and (F) VWF, an endothelial cell marker (red), was examined in a dissected spiral artery treated with 
extravillous trophoblast (EVT) conditioned media (G, merge). EC indicates endothelial cells; and VSM, vascular smooth muscle. Negative 
control (inset) was incubated with nonimmune IgG in place of primary antibody. Scale bar, 50 µm.
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which allows migration of both EC and VSMC. It is capable of 
stimulating EC motility and tube formation in a mouse angio-
genesis plug assay,31 and activation of MMP-1, and causes EC 
network regression by degradation of collagen.32 Also upregu-
lated by trophoblast-secreted factors were the cytokines IL-11 
and IL-6, both members of the IL-6–type cytokine family. 
IL-6 is expressed in myometrial arteries33 and is downregu-
lated in VSMC by cell–cell contact with trophoblast, yet can 
also be upregulated by the secreted factor TNF-α.12 IL-6 is a 
proinflammatory cytokine and may affect EVT invasion and 
cytokine expression.34 The related cytokine IL-11 is associated 
with implantation and is localized to first trimester decidual EC 
Figure 5.  The role of IFN-γ in C-X-C motif chemokine 10 (CXCL10) expression. A, Recombinant IFN-γ induces CXCL10 expression in 
vascular spheroids. Control or rhIFN-γ was added to spheroids made of endothelial cell (EC) alone, vascular smooth muscle cell (VSMC) 
alone, or cocultured EC/VSMC. CXCL10 expression was measured by Western blot analysis (n=4). B, Neutralizing IFN-γ in extravillous 
trophoblast (EVT) conditioned media (CM) decreased vascular spheroid CXCL10 expression. Control media or EVT CM was incubated 
with IFN-γ–neutralizing antibody or corresponding IgG control and added to EC/VSMC spheroids. CXCL10 expression was determined 
by Western blot analysis. *P<0.05 (n=5).
Figure 6. The effects of extravillous tro-
phoblast (EVT) conditioned media (CM) 
and C-X-C motif chemokine 10 (CXCL10) 
on vascular smooth muscle cells 
(VSMCs). VSMCs were incubated for 72 
hours in media containing 0.5% FCS, 
then a further 72 hours with indicated 
concentrations of EVT CM and recombi-
nant human CXCL10 (n=at least 5 inde-
pendent experiments). Expression of (A) 
α-smooth muscle actin and (B) calponin 
was examined by Western blot analysis. 
Time-lapse microscopy was used to 
analyze the effects of rhCXCL10 (C) and 
EVT CM (D) on VSMC motility during a 
24-hour incubation. Data are displayed 
as the mean±SEM of a minimum of 3 
pooled experiments. *P<0.05; **P<0.01.
 at St George's, University of London on February 28, 2013http://atvb.ahajournals.org/Downloaded from 
Wallace et al Trophoblast-Induced CXCL10 in SA Remodeling  e99
and VSMC, and although its role in these vessels is unknown,35 
it has been shown to inhibit VSMC proliferation,36 and as such 
these 2 related cytokines have the potential for multiple effects 
in SA remodeling. Similarly, placental growth factor has been 
associated with apoptosis in vessel remodeling37 and with the 
regulation of VEGF-dependent remodeling.38 The expression 
of platelet-derived growth factor-BB that is known to stimu-
late the dedifferentiation of VSMC39 was increased in response 
to trophoblast-secreted factors, as were 2 transcription factors, 
KLF-4 and c-myc, which are implicated in the mediation of 
this effect.40 Therefore, these selected genes, and several oth-
ers identified by this array, are useful targets that may contrib-
ute to the vessel remodeling process by their expression in EC 
and VSMC in SA.
Expression of the chemokine CXCL10 (previously known as 
IP-10) was found to be significantly upregulated in vascular spher-
oids and first trimester SA explants after treatment with EVT CM. 
It was also expressed by VSMC in the proximity of first trimester 
SA. However, to our knowledge, this is the first report implicat-
ing trophoblast-induced changes in CXCL10 in the physiological 
remodeling of maternal SA. CXCL10 modulates growth, che-
motaxis, and angiogenesis by binding to the CXCR3 receptor41 
and a further unidentified receptor.42 It is angiostatic in vitro and 
in vivo,28 and inhibits both EC proliferation and the induction of 
apoptosis.43,44 CXCL10 and CXCR3 have been associated with 
vessel remodeling, and are associated with vessel regression in 
wound repair.28 In support of this, CXCR3 knockout mice exhibit 
persistent angiogenesis during wound repair.45
Regulation of CXCL10 expression by vascular cells is likely 
to be multifactorial. Major stimuli in a number of cell types, 
including in uterine microvascular EC,21 are proinflammatory 
cytokines, including IFN-γ. Others have reported that IFN-γ 
is released by first trimester trophoblast,29 and using a neutral-
izing antibody, we were able to demonstrate a role for IFN-
γ in our study of vascular remodeling. We found enhanced 
CXCL10 expression in coculture spheroids versus spheroids 
made up of each individual cell type, indicating that interac-
tions between EC and VSMC are important in the induction 
CXCL10. One explanation for this response is that invading 
trophoblast secret bioactive molecules that stimulate EC and 
VSMC to produce factors that act via paracrine or autocrine 
mechanisms to enhance the effects of IFN-γ. It is interesting 
to note that platelet-derived growth factor expression, which 
is significantly upregulated in the coculture system described 
above, has been shown to act synergistically with IFN-γ to 
stimulate CXCL10 expression in other cell systems.46
In support of our in vitro findings, we have demonstrated 
that CXCL10 is expressed in α-smooth muscle actin posi-
tive cells in first trimester decidual sections. Interestingly, 
some cells expressing CXCL10 were found at some distance 
from the vessel lumen. We therefore investigated the role of 
both EVT CM and CXCL10 signaling on VSMC and found 
increased motility, as well as other functional markers of 
dedifferentiation. Recently, the migration of VSMC from 
the arteries has been associated with remodeling by tropho-
blast,47 a process unique to remodeling in the decidua. Other 
mechanisms of disappearance of VSMC during artery remod-
eling are unknown, however, disruption and disorganization 
of the VSMC layer has been attributed to both apoptosis and 
dedifferentiation.48 A decrease in α-smooth muscle actin and 
calponin expression was observed in VSMC treated with EVT 
CM, and a small but nonsignificant decrease with rhCXCL10, 
which indicates a switch to a dedifferentiated, synthetic phe-
notype.39 A decrease in α-smooth muscle actin expression has 
been previously demonstrated during SA remodeling, and cells 
with low expression of α-smooth muscle actin were found at a 
distance from artery lumens,49 similar to the CXCL10-positive 
cells demonstrated immunohistochemically in our study.
Evidence indicates that trophoblast synthesize and secretes 
many factors that could influence the structure of the vessels 
in both a positive and a negative manner, and that it is the bal-
ance between these factors and the way they interact with each 
other that will determine the extent of remodeling. VSMC 
have been demonstrated to express CXCR3, the receptor for 
CXCL10,50,51 and, indeed, we demonstrate CXCR3 expression 
in α-smooth muscle-expressing cells in the decidua. CXCL10 
can also signal via a CXCR3-independent mechanism.42 As 
increased proliferation and motility are markers of VSMC 
dedifferentiation,52 autocrine expression and signaling of 
CXCL10 by VSMC may induce their motility. This has been 
demonstrated in other cell models, and so therefore may be 
possible in first trimester decidua.53,54 It is also possible that 
the release of factors such as CXCL10 act as chemokines 
to recruit interstitial trophoblasts or maternal immune cells, 
such as decidual natural killer cells, to the remodeling vessel, 
which are known to influence both EC and VSMC.55
In conclusion, we have investigated trophoblast-induced 
changes in human decidual SA remodeling using a 3D spheroid 
culture system to model the interactions that occur between the 
different cell types in vivo.24 We have described the potential of 
trophoblast-secreted factors, and the resulting increased CXCL10 
expression to contribute to SA remodeling during pregnancy by 
altering the motility and differentiation status of the VSMC com-
partment of the vessel. Collectively, these results highlight the 
importance of 3D modeling in examining vascular interactions 
and provide new insights in to the mechanism of SA remodeling.
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Supplemental Material 
Supplemental Methods 
Materials and reagents 
L-glutamine, penicillin, streptomycin and endothelial cell growth supplement were obtained 
from Sigma (Dorset, UK). CXCL10, calponin and tubulin antibodies were purchased from 
Abcam (Cambridge, UK) and Santa Cruz (Heidelberg, Germany) and Vectashield mounting 
medium from Vector Labs (Peterborough, UK).  CXCL10 recombinant protein was 
purchased from R & D Systems (Abingdon, UK). Vivaspin columns were purchased from 
Sartorious Stedim Biotech (Aubagne, France).  
 
Cell culture  
The human vascular smooth muscle cell line SGHVSMC-9 (VSMC), derived from 
transfected human aortic vascular smooth muscle cells, was maintained as previously 
described 1 in Ham’s F10 medium (Invitrogen Life Technologies, Paisley, UK)  supplemented 
with 10% (v/v) fetal bovine serum (FBS), L-glutamine (2 mmol/L), penicillin (100 IU/ml), and 
streptomycin (100 µg/ml). This cell line has been well characterised for use in these studies 
2, 3 The human endothelial cell line SGHEC-7 was maintained as previously described 4 in 
Medium 199 supplemented with Earle's modifed salts (M199; GIBCO Invitrogen, UK): RPMI 
1640 (Sigma, UK) medium in a ratio of 1:1 containing L-glutamine (2 mmol/L), penicillin (100 
IU/ml), streptomycin (100 µg/ml), gentamicin (16mg/ml), supplemented with endothelial cell 
growth supplement (ECGS, 2.5 µg/ml) and 10% (v/v) FBS.  The well characterised human 
extravillous trophoblast (EVT) cell line SGHPL-4 was derived from primary human first 
trimester EVT5. SGHPL-4 cells were cultured in Hams F10 media supplemented with 10% 
(v/v) FBS, containing L-glutamine (2 mmol/L), penicillin (100 IU/ml), and streptomycin (100 
µg/ml). All cells were incubated with 95% air and 5% carbon dioxide at 37°C in a humidified 
incubator.  
 
Generation of EVT conditioned media 
SGHPL-4 cells were grown in 3-dimensional culture as previously described 6. Briefly, 4x106 
cells were added to 25ml Universal tubes containing 20mg of gelatin-coated Cytodex-3 
microcarrier beads (Sigma) and cultured on a spiralex roller at 37°C in phenol-red-free 
RPMI-1640 (GIBCO) containing 10% (v/v) FCS and 25mM Hepes buffer. After 24 h the 
medium was removed and the cells and beads washed twice with PBS. Medium was then 
replaced with phenol-red-free RPMI-1640 containing 25mM Hepes. Conditioned medium 
(CM) was collected after 48 h, spun at 5000g through a Vivaspin 20 (3000 mwco PES) 
column at 4oC. The concentrated media was then made up to x1 with phenol-red-free RPMI-
1640 and this centrifugation step repeated. The protein concentration of the resulting 
concentrated CM was determined by Bradford assay and stored at -20°C at a final 
concentration of 0.5µg/µl. IFN-γ was neutralised in CM by 1 hour pre-incubation with mouse 
anti-human IFN-γ (0.3 µg/ml, R&D systems, MAB2852) or control mouse IgG (0.3 µg/ml, 
Sigma) before use in experiments. 
 
Spheroid generation and treatments 
To generate spheroids, a hanging drop culture method was used 7, 8. VSMC and SGHEC-7 
were cultured alone or in co-culture in equal numbers in VSMC media containing 0.5% (v/v) 
FBS and 25% (v/v) carboxymethylcellulose and 30 µl containing a total of 1500 cells (co-
culture: 750 VSMC and 750 SGHEC-7) was placed on the underside of a petri dish lid. 
Spheroids were left to form for 24 hours before use in experiments. The following treatments 
were added to the spheroids for 24 hours: EVT CM at a concentration of 71 ng / µl, rhIFN-γ 
(500 U/ml, R&D systems), IFN-γ neutralised CM as above. Phenol-red free RPMI 1640 
media was added to spheroids as a control. At the end of the incubation period, spheroids 
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(n=64) were collected, pooled, and washed 3 x in PBS. Spheroids were then lysed for 
microarray, RNA isolation or protein isolation, or fixed in 4% (w/v) paraformaldehyde in PBS 
for immunohistochemical analysis.   
  
RNA isolation 
RNA was extracted using RNEasy mini kit according to manufacturer’s instructions (Qiagen, 
West Sussex, UK). 
 
Microarray analysis 
RNA was reverse transcribed into cDNA, amplified and transcribed into cRNA using the 
Illumina TotalPrep RNA amplification kit (Ambion, Life Technologies, Warrington, UK) 
according to manufacturer’s instructions. The cRNA was then assessed for quantity and 
quality by Agilent RNA 6000 Pico Kit (Agilent Technologies, Germany) and NanoDrop 
(ThermoScientific, West Sussex, UK) and hybridised to Illumina Sentrix BeadChip Array 
Human HT-12_v4_Beadchip (Illumina) according to manufacturer’s instructions, and 
scanned on an Illumina GX500 Beadstation. Idat files were imported to GenomeStudio 
(Illumina) and raw data exported in text format. Data comparing spheroids treated with 
trophoblast conditioned or control media was analysed in GeneSpring v11.5.1 (Agilent 
Technologies). In brief data was normalised using quantile normalisation and baseline 
transformed to the median of all control samples. Sample distributions were checked for 
consistency and conformity to a gausian distribution by qualitative methods and replicate 
consistency was assessed using principal component analysis. Data was filtered to remove 
unexpressed or unreliable data such that remaining entities should have a detection p-value 
of greater than 0.6 in 100% of samples for any one of the two conditions and a fold change 
of greater than 1.5 compared to the control. An unpaired t-test was performed in conjunction 
with a Benjemini-Hochberg multiple testing correction and a corrected p-value of <0.05 was 
applied. GO analysis was performed using a corrected p-value  of <0.05. Microarray data 
are available in the ArrayExpress database (www.ebi.ac.uk/arrayexpress) under accession 
number E-MTAB-1462.  
 
SYBR green quantitative RT-PCR analysis 
Spheroid RNA samples (64 spheroids per experiment, n=3) were reverse transcribed using 
Bioline cDNA Synthesis kit according to manufacturer’s instructions (Bioline, London, UK). 
40ng of cDNA was used in duplicate samples for quantitative RT-PCR using Power SYBR 
green Master Mix (Applied Biosystems, Life Technologies) as manufacturer’s instructions 
using the following sequence specific primers: 
18S: ACA-CGT-TCC-ACC-TCA-TCC-TC and CTT-TGC-CAT-CAC-TGC-CAT-TA 
CXCL10:TTC-AAG-GAG-TAC-CTC-TCT-CTA-G and CTG-GAT-TCA-GAC-ATC-TCT-TCT-C 
STC-1: CAG-GCT-TCG-GAC-AAG-TCT-GT and ACA-GCA-AGC-TGA-ATG-TGT-GC 
PGF - GTC-TCC-TCC-TTT-CCG-GCT-T and TGC-AGC-TCC-TAA-AGA-TCC-GTT 
Q-PCR was carried out using a Bio-Rad CFX96 Real-Time PCR Detection System (Bio-Rad, 
Hemel Hempstead, UK). Expression of analysed genes was normalised to RNA loading for 
each sample using the 18S ribosomal RNA as an internal standard. 
 
Western Blot Analysis 
Protein was resolved on 8–10% sodium dodecyl sulphate (SDS)–polyacrylamide gels before 
transfer onto Hybond P membrane (Amersham, UK). Non-specific reactivity was blocked 
with 5% (w/v) non-fat dried milk in Tris-buffered saline containing 0.1% (v/v) Tween-20 
(TBST) for 1 h at room temperature. Blots were incubated overnight at 4°C with rabbit anti 
CXCL10 (0.5 µg/ml, Abcam ab9807), mouse anti α-smooth muscle actin (0.1 µg/ml, 
Dako,clone 1A4) or rabbit anti-calponin (1:1000, Abcam ab46794). Peroxidase conjugated 
secondary antibodies (1:10000, Sigma) were incubated at room temperature for 1 h and 
detection was performed using ECL Plus (Millipore, Watford, UK). Blots were subsequently 
blocked and re-probed with a mouse anti tubulin antibody (0.15 µg/ml, Abcam, ab11323). 
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Western blots were scanned and the integrated intensity of each band determined using 
ImageJ version 1.43u. Western blots shown are representative of at least three separate 
experiments and expressed as a ratio to tubulin in the same sample. 
Ex vivo vessel explant model 
Informed consent was obtained and ethical committee approval was in place for all studies. 
Decidual/myometrial biopsies (n=3) were obtained from pregnant women undergoing 
elective Caesarean section at term for reasons such as breech presentation. These were 
taken from non-placental bed areas from the upper leaf of the lower segment Caesarean 
incision. In event of a placenta low-lying in the lower segment, uterine biopsies were likely to 
be from placental bed and so were not taken because of the risk of maternal post-partum 
haemorrhage. Spiral arteries were dissected as previously described 9 using a stereo 
microscope with minimal surrounding tissue. Vessels were incubated in individual wells of a 
96 well plate with EVT conditioned media for 24 hours, before being snap-frozen and 
cryosectioned for immunohistochemical staining.  
 
Immunohistochemistry 
Spiral artery immunohistochemistry 
Sections were fixed in 4% (w/v) paraformaldehyde in PBS for 10 minutes, washed in PBS, 
and permeabilized in 0.2% (v/v) Triton X-100 in PBS for 5 minutes. After 3 washes with PBS, 
blocking buffer (PBS in 10% (v/v) goat serum) was added for 30 minutes, then sections were 
incubated in mouse anti-human CXCL10 antibody (2 µg/ml, Santa Cruz, sc101500), or 
isotype control immunoglobulin overnight at 4°C. After 3 washes, sections were incubated 
for 30 minutes with biotinylated goat anti-mouse (7.5 µg/ml, Vector Laboratories). After 3 
further washes, sections were incubated with fluorescein-streptavidin (15 µg/mL, Vector 
Laboratories) for 45 minutes. Sections were then re-blocked in normal goat serum and rabbit 
anti-VWF antibody (17.1 µg/ml, Dako, UK) was added for 1 hour at room temperature. 
Sections were then incubated with goat anti-rabbit Alexafluor 546 (Molecular probes, 
Invitrogen, UK) for 45 minutes, washed extensively, and mounted using Vectashield 
mounting medium with DAPI to visualise nuclei. 
 
Spheroid immunohistochemistry 
Spheroids were washed with PBS and fixed in 4% (w/v) paraformaldehyde in PBS for 10 
minutes and then washed in fixative buffer (30% (w/v) sucrose, 90mM MgCl2 in 2X PBS). 
Spheroids were then suspended in a small volume of 1.5% (w/v) agarose/5% (w/v) sucrose 
in PBS which was allowed to set. The resultant blocks were placed in a 30% (w/v) sucrose in 
water solution until each block had sunk. Blocks were then frozen on dry ice and 
cryosectioned in 15 µm sections through roughly the centre of the spheroid. Spheroid 
sections were then immunostained as spiral artery sections.  
 
Decidual immunohistochemistry 
Products of conception were obtained from women attending clinic for elective termination of 
pregnancy between 9-12 weeks. Research Ethics Committee approval was in place and all 
women gave informed written consent. Decidual fragments were fixed in formalin, paraffin 
embedded and 10µm sections cut.  
Slides were dewaxed in xylene for 10 minutes followed by rehydration through graded 
ethanol (100%, 95%, 80%, and 70%) for 20 seconds each and a final wash in water. Antigen 
retrieval was performed in boiling citrate buffer (0.01M, pH 6) for 5 minutes and left to stand 
for a further 20 minutes. Endogenous peroxidase activity was then blocked by washing 
sections in 3% (v/v) hydrogen peroxide in methanol. After a brief wash in tap water slides 
were washed in Tris buffered saline (TBS, pH 7.5) twice for 5 minutes each. Sections were 
then incubated in 10% normal goat serum for at least 30 minutes at room temperature. 
Mouse anti-human CXCL10 antibody (2 µg/ml, Santa Cruz), mouse anti-human smooth 
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muscle actin antibody (0.2 µg/ml Dako, UK clone 1A4), mouse anti-cytokeratin 7 antibody 
(3.1 µg/ml, DAKO clone OV-TL 12/30) or mouse anti-CXCR3 antibody (3.3 µg/ml, Abcam 
ab64714) was then applied and incubated at 4 °C overnight. Control sections were included 
with non-immune IgG. Following further washes in TBS, the biotinylated and horseradish 
peroxidase-conjugated secondary antibody was applied for 10 minutes at room temperature 
(Histofine kit, Invitrogen, UK).  Sections were incubated with DAB (DAKO, UK) for 1-5 
minutes until positive staining was identified by a brown colour under x10 magnification. 
Sections were then counterstained for 1-5 minutes in haemotoxylin, mounted and visualised. 
 
Confocal microscopy 
For confocal analysis, before co-culture and spheroid generation cells were incubated for 30 
minutes at 37°C with 1 nM CellTrackerTM Green or Orange (Molecular Probes, Invitrogen, 
UK). Spheroids  were then mounted in 80% (v/v) glycerol on a concave slide. The spheroids 
were analysed using a confocal laser scanning microscope (CLSM) with an LSM 510 Meta 
inverted microscope (Zeiss, Hertfordshire, UK) and the LSM 510 image examiner software 
(Zeiss).  
 
Time-lapse microscopy 
 
Motility of VSMC was observed over time using an Olympus IX70 inverted microscope 
equipped with a Hamamatsu C4742-95 digital camera. VSMC were incubated in medium 
containing 0.5% (v/v) FBS for 24 h, at which point they were transferred to the microscope 
chamber in fresh medium containing vehicle (PBS) or indicated concentrations of CXCL10 or 
conditioned media. The microscope and stage were enclosed within a heated (37°C) 
chamber (Solent Scientific, UK) and cells were cultured in 5% CO2 in air. Images were 
captured every 15 min for 24 hours and analysed using Image Pro Plus software (Media 
Cybernetics, USA). For analysis, 20 cells in 2 fields of view for each treatment were chosen 
at random at the beginning of the time-lapse sequence and the distance moved by each cell 
recorded. 
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Supplemental Tables 
Supplemental Table I: Vascular spheroid gene expression altered over 1.5 fold by 
trophoblast conditioned media 
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Gene Name / Symbol  Fold change 
absolute 
Corrected p‐
value 
Up / down 
Homo sapiens CD93 molecule (CD93), mRNA.  2.594932 0.006259621 up 
Homo sapiens stanniocalcin 1 (STC1), mRNA.  2.340758 0.001881272 up 
Homo sapiens chemokine (C‐C motif) ligand 20 (CCL20), mRNA.  2.278803 0.037411097 up 
Homo sapiens podocalyxin‐like (PODXL), transcript variant 1, mRNA.  2.276604 0.011221726 up 
Homo sapiens chemokine (C‐X‐C motif) ligand 10 (CXCL10), mRNA.  2.241451 0.020344842 up 
Homo sapiens interleukin 6 (interferon, beta 2) (IL6), mRNA.  2.208562 0.02667893 up 
Homo sapiens tissue factor pathway inhibitor 2 (TFPI2), mRNA. 2.202464 0.015408089 up 
Homo sapiens transmembrane protein 158 (TMEM158), mRNA. 2.152755 0.006259621 up 
Homo sapiens interleukin 11 (IL11), mRNA.  2.143356 0.008667579 up 
Homo sapiens placental growth factor (PGF), mRNA. 2.018083 0.015408089 up 
Homo sapiens hedgehog interacting protein (HHIP), mRNA. 1.998893 0.017495126 up 
Homo sapiens interleukin 8 (IL8), mRNA.  1.943614 0.020018023 up 
Homo sapiens chemokine (C‐X‐C motif) receptor 4 (CXCR4), transcript variant 2, mRNA.  1.935163 0.008772412 up 
Homo sapiens podocalyxin‐like (PODXL), transcript variant 1, mRNA.  1.925909 0.008772412 up 
Homo sapiens prostaglandin‐endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (PTGS2), mRNA.  1.875883 0.027641652 up 
Homo sapiens secretogranin V (7B2 protein) (SCG5), mRNA.  1.871887 0.001881272 up 
Homo sapiens coagulation factor II (thrombin) receptor‐like 1 (F2RL1), mRNA.  1.870356 0.012442495 up 
Homo sapiens matrix metallopeptidase 10 (stromelysin 2) (MMP10), mRNA.  1.859341 0.037411097 up 
Homo sapiens serum/glucocorticoid regulated kinase 1 (SGK1), transcript variant 1, mRNA.  1.8578 0.020344842 up 
Homo sapiens serum/glucocorticoid regulated kinase (SGK), mRNA.  1.838739 0.02667893 up
Homo sapiens KIAA1199 (KIAA1199), mRNA.  1.825166 0.032360554 up 
Homo sapiens tumor necrosis factor, alpha‐induced protein 6 (TNFAIP6), mRNA.  1.79597 0.023012258 up 
Homo sapiens solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 24 (SLC25A24), nuclear gene encoding
mitochondrial protein, transcript variant 1, mRNA.  1.774163 0.036931 up 
Homo sapiens dishevelled associated activator of morphogenesis 1 (DAAM1), mRNA. 1.773732 0.017495126 up 
Homo sapiens neurotrimin (NTM), transcript variant 2, mRNA. 1.766954 0.006259621 up 
Homo sapiens phosphodiesterase 4B, cAMP‐specific (phosphodiesterase E4 dunce homolog, Drosophila) (PDE4B), transcript variant a, 
mRNA.  1.757134 0.019516693 up 
Homo sapiens NADPH oxidase 4 (NOX4), mRNA.  1.755237 0.008667579 up 
Homo sapiens coagulation factor II (thrombin) receptor‐like 1 (F2RL1), mRNA.  1.746881 0.028023487 up 
Homo sapiens collagen, type VI, alpha 3 (COL6A3), transcript variant 3, mRNA.  1.736037 0.021656875 up 
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Homo sapiens gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis) (GREM1), mRNA.  1.708331 0.042738255 up 
Homo sapiens serpin peptidase inhibitor, clade B (ovalbumin), member 2 (SERPINB2), mRNA.  1.704612 0.030201832 up 
Homo sapiens regulator of G‐protein signalling 4 (RGS4), mRNA.  1.702098 0.042020477 up 
Homo sapiens collagen, type VI, alpha 3 (COL6A3), transcript variant 1, mRNA.  1.696903 0.02667893 up 
Homo sapiens dual specificity phosphatase 6 (DUSP6), transcript variant 2, mRNA.  1.688827 0.021656875 up 
Homo sapiens SRY (sex determining region Y)‐box 18 (SOX18), mRNA.  1.684359 0.017021826 up 
Homo sapiens cadherin 5, type 2, VE‐cadherin (vascular epithelium) (CDH5), mRNA.  1.683726 0.02667893 up 
Homo sapiens endothelial cell‐specific molecule 1 (ESM1), mRNA.  1.680873 0.037411097 up 
Homo sapiens serum/glucocorticoid regulated kinase 1 (SGK1), transcript variant 1, mRNA.  1.664353 0.024545638 up 
Homo sapiens platelet‐derived growth factor beta polypeptide (simian sarcoma viral (v‐sis) oncogene homolog) (PDGFB), transcript 
variant 1, mRNA.  1.661473 0.02667893 up 
Homo sapiens prostate transmembrane protein, androgen induced 1 (PMEPA1), transcript variant 2, mRNA. 1.652479 0.031239437 up 
PREDICTED: Homo sapiens hypothetical protein LOC440345, transcript variant 6 (LOC440345), mRNA. 1.652412 0.006259621 down 
Homo sapiens dual specificity phosphatase 6 (DUSP6), transcript variant 1, mRNA. 1.65127 0.021656875 up 
Homo sapiens septin 4 (SEPT4), transcript variant 2, mRNA.  1.649398 0.047301278 down 
Homo sapiens growth arrest‐specific 1 (GAS1), mRNA.  1.648486 0.022904437 up 
Homo sapiens nuclear receptor subfamily 4, group A, member 2 (NR4A2), transcript variant 1, mRNA.  1.645724 0.023800679 up 
Homo sapiens guanylate binding protein 1, interferon‐inducible, 67kDa (GBP1), mRNA.  1.641342 0.020344842 up 
Homo sapiens thrombomodulin (THBD), mRNA.  1.639041 0.017021826 up 
Homo sapiens protein tyrosine phosphatase, receptor type, E (PTPRE), transcript variant 2, mRNA.  1.637211 0.025211982 up 
Homo sapiens endothelial cell‐specific molecule 1 (ESM1), mRNA.  1.633846 0.03043533 up 
Homo sapiens cyclin D1 (CCND1), mRNA.  1.631296 0.015408089 up
Homo sapiens LFNG O‐fucosylpeptide 3‐beta‐N‐acetylglucosaminyltransferase (LFNG), transcript variant 1, mRNA.  1.629187 6.67E-04 up 
Homo sapiens plexin A2 (PLXNA2), mRNA.  1.626524 0.008667579 up 
Homo sapiens HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2 (HECW2), mRNA. 1.626333 0.015408089 up 
Homo sapiens EGF, latrophilin and seven transmembrane domain containing 1 (ELTD1), mRNA. 1.625174 0.015408089 up 
Homo sapiens prostate transmembrane protein, androgen induced 1 (PMEPA1), transcript variant 2, mRNA. 1.624929 0.015408089 up 
Homo sapiens adenomatosis polyposis coli down‐regulated 1‐like (APCDD1L), mRNA. 1.617783 0.022904437 up 
Homo sapiens endothelial differentiation, sphingolipid G‐protein‐coupled receptor, 1 (EDG1), mRNA. 1.613336 0.028148912 up 
Homo sapiens chromosome 4 open reading frame 49 (C4orf49), mRNA. 1.596915 0.022904437 down 
Homo sapiens tribbles homolog 1 (Drosophila) (TRIB1), mRNA.  1.587401 0.02667893 up 
Homo sapiens cathepsin C (CTSC), transcript variant 1, mRNA.  1.581769 0.001881272 up 
Homo sapiens 5'‐nucleotidase, ecto (CD73) (NT5E), mRNA.  1.581389 0.017495126 up 
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Homo sapiens potassium voltage‐gated channel, shaker‐related subfamily, beta member 1 (KCNAB1), transcript variant 2, mRNA. 
1.579729 0.018453117 up 
Homo sapiens platelet‐derived growth factor beta polypeptide (simian sarcoma viral (v‐sis) oncogene homolog) (PDGFB), transcript 
variant 2, mRNA.  1.575343 0.022904437 up 
Homo sapiens glutamine‐fructose‐6‐phosphate transaminase 2 (GFPT2), mRNA. 1.57108 0.022904437 up 
Homo sapiens pleckstrin 2 (PLEK2), mRNA.  1.568859 0.012779525 up 
Homo sapiens lipase, endothelial (LIPG), mRNA.  1.568142 0.019516693 up 
Homo sapiens SH2 domain containing 3C (SH2D3C), transcript variant 2, mRNA.  1.567942 0.023925005 up 
Homo sapiens dehydrogenase/reductase (SDR family) member 3 (DHRS3), mRNA.  1.56785 0.011221726 down 
Homo sapiens Epstein‐Barr virus induced gene 2 (lymphocyte‐specific G protein‐coupled receptor) (EBI2), mRNA.  1.566772 0.022904437 up 
Homo sapiens protein tyrosine phosphatase, receptor type, E (PTPRE), transcript variant 2, mRNA.  1.566606 0.02086765 up 
Homo sapiens heparin‐binding EGF‐like growth factor (HBEGF), mRNA.  1.565329 0.02667893 up 
Homo sapiens v‐myc myelocytomatosis viral oncogene homolog (avian) (MYC), mRNA.  1.563026 0.02667893 up 
Homo sapiens serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 (SERPINE2), mRNA.  1.561675 0.009054425 up 
Homo sapiens interleukin 1, alpha (IL1A), mRNA.  1.559357 0.020344842 up 
Homo sapiens glutathione peroxidase 3 (plasma) (GPX3), mRNA.  1.558923 0.017021826 down 
Homo sapiens small Cajal body‐specific RNA 14 (SCARNA14), guide RNA. 1.555441 0.03776642 up 
Homo sapiens protein kinase (cAMP‐dependent, catalytic) inhibitor alpha (PKIA), transcript variant 7, mRNA. 1.554495 0.017021826 up 
Homo sapiens protein kinase (cAMP‐dependent, catalytic) inhibitor alpha (PKIA), transcript variant 6, mRNA. 1.551958 0.020344842 up 
Homo sapiens cleavage stimulation factor, 3' pre‐RNA, subunit 3, 77kDa (CSTF3), transcript variant 3, mRNA. 1.551671 0.017021826 down 
Homo sapiens wingless‐type MMTV integration site family, member 5A (WNT5A), mRNA. 1.548196 0.037411097 up 
Homo sapiens MAM domain containing 2 (MAMDC2), mRNA. 1.544279 0.008667579 up 
Homo sapiens CD44 molecule (Indian blood group) (CD44), transcript variant 4, mRNA.  1.540968 0.02667893 up 
Homo sapiens hypothetical LOC100216001 (LOC100216001), non‐coding RNA.  1.538554 0.008772412 up 
Homo sapiens transmembrane protein 200A (TMEM200A), mRNA.  1.537259 0.017021826 up 
Homo sapiens latent transforming growth factor beta binding protein 2 (LTBP2), mRNA.  1.536061 0.008667579 up 
Homo sapiens phosphodiesterase 4B, cAMP‐specific (phosphodiesterase E4 dunce homolog, Drosophila) (PDE4B), transcript variant a, 
mRNA.  1.535905 0.02667893 up 
Homo sapiens phosphodiesterase 7B (PDE7B), mRNA.  1.534708 0.008667579 up
Homo sapiens sphingosine‐1‐phosphate receptor 1 (S1PR1), mRNA.  1.529714 0.022904437 up 
Homo sapiens chemokine (C‐X‐C motif) receptor 4 (CXCR4), transcript variant 1, mRNA.  1.529364 0.017021826 up 
Homo sapiens OCIA domain containing 2 (OCIAD2), transcript variant 2, mRNA. 1.526341 0.011221726 up 
Homo sapiens mRNA; cDNA DKFZp762M127 (from clone DKFZp762M127) 1.525293 0.028023487 up 
Homo sapiens nucleolar protein 12 (NOL12), mRNA. 1.519159 0.03043533 down 
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Homo sapiens chromosome 4 open reading frame 18 (C4orf18), transcript variant 2, mRNA.  1.514323 0.017021826 up 
Homo sapiens pterin‐4 alpha‐carbinolamine dehydratase/dimerization cofactor of hepatocyte nuclear factor 1 alpha (PCBD1), mRNA.  1.511084 0.015408089 down 
Homo sapiens sushi‐repeat‐containing protein, X‐linked 2 (SRPX2), mRNA.  1.510306 0.017495126 up 
Homo sapiens Parkinson disease 7 domain containing 1 (PDDC1), mRNA.  1.508039 0.02171086 down 
Homo sapiens hypothetical locus LOC401237 (FLJ22536), non‐coding RNA.  1.506264 0.007810248 up 
Homo sapiens sushi‐repeat‐containing protein, X‐linked (SRPX), mRNA.  1.505457 0.017021826 up 
Homo sapiens hyaluronoglucosaminidase 2 (HYAL2), transcript variant 1, mRNA.  1.505197 0.022904437 up 
full‐length cDNA clone CS0DA009YB08 of Neuroblastoma of Homo sapiens (human)  1.502986 0.02667893 up 
Homo sapiens Kruppel‐like factor 4 (gut) (KLF4), mRNA.  1.502778 0.020344842 up 
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Supplemental Table II: Full list of gene ontologies of vascular spheroid gene expression 
altered over 1.5 fold by trophoblast conditioned media 
Biological Process Number 
of genes 
P value 
Regulation of cell proliferation 16 9.08E-05 
Response to wounding 15 9.08E-05 
Response to external stimulus 17 3.92E-04 
Response to stress 23 1.00E-03 
Organ morphogenesis 11 7.00E-03 
Regulation of locomotion 8 7.00E-03 
Organ development 20 9.00E-03 
Regulation of phosphorylation 12 0.009 
Regulation of phosphorus metabolic process 13 1.10E-02 
Regulation of phosphate metabolic process 13 1.10E-02 
Cell-cell signaling 11 1.10E-02 
Negative regulation of cell proliferation 8 1.20E-02 
Signal transduction 37 0.014 
Cell communication 39 0.014 
Positive regulation of cell proliferation 9 0.014 
Inflammatory response 9 0.017 
Anatomical structure morphogenesis 14 0.022 
Regulation of cell migration 6 0.022 
Regulation of localization 10 0.031 
Regulation of cellular component movement 6 0.033 
Angiogenesis 5 0.033 
Blood vessel development 6 0.033 
Vasculature development 6 0.036 
Regulation of protein kinase activity 9 0.036 
Regulation of map kinase activity 6 0.036 
Anatomical structure development 23 0.036 
System development 22 0.037 
Regulation of kinase activity 9 0.037 
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Regulation of transferase activity 9 0.041 
Negative regulation of protein kinase activity 4 0.043 
Positive regulation of peptidyl serine phosphorylation 2 0.043 
Regulation of peptidyl serine phosphorylation 2 0.043 
Negative regulation of kinase activity 4 0.043 
Biological regulation 54 0.043 
Response to stimulus 27 0.043 
Negative regulation of transferase activity  4 0.046 
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Supplemental Figure I 
 
 
 
Supplemental Figure I: CXCL10 mRNA expression timecourse. mRNA expression in 
vascular spheroids was measured by quantitative RT-PCR after stimulation with trophoblast 
conditioned media (CM) for 8, 24 or 48 hours (n= at least 4). Data are expressed as mRNA 
expression relative to an external calibrator. All data are presented as mean + SEM. * 
Denotes p < 0.05 relative to control spheroids.  
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Supplemental Figure II 
  
Supplemental Figure II: CXCR3 protein is expressed by first trimester decidua and co-
localises with α-smooth muscle actin protein expressionA: CXCR3 and B: α-smooth 
muscle actin protein expression was examined by immunohistochemistry in serially 
sectioned first trimester decidua (n=5; representative image shown). CXCR3 and α-smooth 
muscle actin protein co-localised to the same cells (indicated by arrowheads). Negative 
control (inset) was incubated with non-immune IgG in place of primary antibody, scale bar 
represents 50 µm. Both proteins were present at a time of trophoblast invasion as shown by 
positive CK7 immunohistochmistry (C). 
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